Research Group Martin Hüllner

Keywords

PET/MR; PET/CT; Oncologic imaging; Image reconstruction; Neuroimaging

Summary & Mission statement

Our group is dedicated to advancing novel multimodal hybrid imaging in oncology and neurology — spanning the entire spectrum from the development and clinical translation of innovative radiotracers to acquisition optimization and image interpretation. We aim to harness the intersection of imaging technology, medical physics, and radiopharmaceutical science to enhance clinical decision-making and ultimately improve patient outcomes.

Overview

The advent of simultaneous hybrid imaging, particularly PET/MR, has fundamentally transformed our understanding of anatomical lesions in both oncological and neurological diseases, as well as our ability to characterize therapy-induced tissue changes. Leveraging deep learning, we have demonstrated that hardware limitations in imaging can be effectively overcome, setting new standards for image reconstruction in these fields. Building on this foundation, we aim to further explore how novel radiotracers, advanced acquisition protocols, and cutting-edge reconstruction techniques can improve disease characterization and ultimately contribute to more precise, patient-centered care.

Publications

FDG-negative breast cancer brain metastasis.